Interventions to assist family communication about inherited cancer risk have the potential to improve family cancer outcomes. This review aimed to evaluate the efficacy of proband-mediated interventions employed within genetics clinics to increase disclosure of genetic risk to at-risk relatives. MEDLINE, Embase, CINAHL, PubMed and PsycINFO were searched for publications between 1990–2020. The quality of studies was assessed. From 5605 records reviewed, 9 studies (4 randomised control trials and 5 cohort studies) were included involving families with BRCA1, BRCA2 and Lynch syndrome. Intervention delivery modes included genetic counselling with additional telephone or in-person follow-up, letters, videos, and decision aids. The percentages of at-risk relatives informed by the proband about their risk ranged from 54.0% to 95.5% in the intervention or family-mediated comparison group. Of those who were informed, 24.4–60.0% contacted a genetics clinic and 22.8–76.2% had genetic testing after they were counselled at a genetics clinic. Significant differences between intervention and control group were reported on all three outcomes by one study, and with relatives contacting a genetics clinic by another study. The studies suggest but do not conclusively show, that tailored genetic counselling with additional follow-up can increase both the proportion of informed relatives and relatives who contact the genetics clinic. With the increase in germline testing, interventions are required to consider the family communication process and address post-disclosure variables (e.g., relative’s perceptions, emotional reactions) through engagement with probands and relatives to maximise the public health benefit of identifying inherited cancer risk in families.
Rapid advances have been made in the identification of the aetiology of a wide range of inherited disorders, particularly regarding cancer predisposing germline pathogenic variants. Although variable, the heritable contribution to cancer overall has traditionally been estimated at 5–10%, however, more recent data indicate it may be as high as 33% (95% CI, 30–37%) due to common and rare variants . The discovery of pathogenic variants has impacted clinical practice and outcomes by enabling provision of both personalised cancer risk estimates to individuals and recommendations for increased surveillance or risk-reduction strategies to improve survival.
The detection of pathogenic variants in asymptomatic individuals is potentially lifesaving. However, universal testing of all germline variants in the general population is not feasible and is cost-prohibitive, due to the overall low prevalence of pathogenic variants in the general population . Thus, cascade testing, the direct testing of relatives of known pathogenic variant, is the primary approach employed by clinical genetic services . Before testing of relatives can happen, disclosure of genetic results to the family must occur. This, however, can be problematic with dissemination of information often being left to the proband (the first individual in a family who receives genetic counselling and/or genetic testing), who is typically asked to inform their at-risk relatives about the availability of genetic testing. At-risk relatives are based on genetic relatedness as either first-degree (relative who shares 50% of their DNA with a particular individual; parents, offspring, and siblings) or second-degree (relative who shares 25% of their DNA; grandparent, grandchild, aunt/uncle, half-siblings, and niece/nephew) or third-degree relatives (relative who shares 12.5% of their DNA; first cousins).
Probands can encounter numerous challenges with disclosure. Common barriers include loss of contact with some family members, due to immigration, separation, death, or conflict . Probands may also face emotional barriers such as guilt, anxiety, and concern about burdening relatives or a fear of relationship breakdown [3, 4]. Other barriers are related to lack of language skills, low levels of education, proband misunderstanding and lack of knowledge, or relying on other relatives for dissemination responsibilities . Although reported disclosure rates vary from moderate to high [6,7,8,9,10], subsequent genetic testing in informed relatives remains suboptimal. In a study of dissemination within families with a known breast cancer pathogenic variant (BRCA1 or BRCA2), the overall disclosure rate was 90%, but the rate of subsequent testing was 57% amongst relatives . Some characteristics of relatives with lower BRCA testing rates include, younger relatives, male relatives, relatives of the paternal lineage, including second- or third-degree relatives .
Aiding probands with information and education about the risk for younger, male, and distant at-risk relatives may address some of the barriers.
Direct-mediated approaches (DMA), in which genetics clinics make direct contact with at-risk relatives, seem to be effective in disseminating information by overcoming the challenges faced by probands . Yet, there remain privacy and confidentiality barriers preventing widespread implementation of DMA. Consequently, many genetic centres do not currently have legal authority to override a patient’s autonomy in dissemination of their genetic results  and/or guidelines do not mandate disclosure . Furthermore, many countries do not have the legislation support to maintain a genetic registry which would be required to ensure DMA is conducted comprehensively and efficiently. Thus, the responsibility for family communication of genetic risk remains with probands. Given this situation it is important to synthesise the available data on proband-mediated interventions that address barriers and support probands to communicate with their relatives about genetic results, to better support them in this difficult task.
The aim of this paper was therefore to review the efficacy of proband-mediated interventions to increase disclosure of genetic risk to at-risk relatives, in relation to three main outcomes:
the proportion of at-risk relatives informed about their risk
the proportion of at-risk relatives contacting genetics clinics
the proportion of at-risk relatives having genetic testing after they were counselled at a genetics clinic
Materials and methods
Database search procedure
Databases (MEDLINE, Embase, CINAHL, PubMed and PsycINFO) were searched using appropriate MeSH terms and keywords in the title and abstracts using the following terms: [intervention OR ((decision OR communication) AND (aid OR tool OR instrument))] AND family AND [cancer OR neoplasms OR genetics]. We exported the search results into EndNote X9 (Thomson Reuters) to be screened. The final search was conducted in November 2020, after which snowballing was conducted on all the included studies (both backwards via their reference lists, and forward through their citations as indexed by Google Scholar). The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines  (Supplementary file 1).
Inclusion and exclusion criteria
Articles were included if they addressed the following:
Family communication: Communication between proband and at-risk relatives about the relative’s genetic risk of cancer and/or germline genetic testing.
Intervention: A clinically implementable intervention that had at least one component focused on improving family disclosure or educating probands about talking to relatives about hereditary cancer. Interventions included educational resources (decision aids, websites), and/or genetic counselling strategies.
Study design: Randomised control trials (RCTs), single-arm, and non-randomised control trials.
Genetic condition: hereditary breast-ovarian cancer (BRCA1 or BRCA2) and hereditary non-polyposis colorectal cancer (HNPCC; Lynch syndrome)
Outcomes: Focused on three post-intervention outcomes: 1) the number of at-risk relatives informed about their risk, 2) the number of at-risk relatives contacting genetics clinics, and 3) the number of at-risk relatives having genetic testing after they were counselled at a genetics clinic
Published in a peer-reviewed journal between 1990 and 2020 to find relevant papers after DNA testing was introduced into clinical practice.
Articles were excluded if they:
Addressed general communication with spouses and extended relatives.
Did not address germline genetic testing.
Were a healthcare intervention that did not aim to assist probands in communicating with relatives.
Were conference proceedings, commentary, or reviews.
Were studies including interventions that aimed to improve family communication but only provided qualitative outcome data or provided total scores in which proband-specific data could not be extracted.
We identified 5605 articles after duplicates were removed (Fig. 1). Two authors (A.L.Y. and M.J.S.) independently screened the titles and abstracts against the inclusion criteria (with an inter-rater agreement of 91%) and disagreements were resolved after discussion. A hundred and five full-text articles were reviewed, and a final nine articles met inclusion criteria. Two were identified through snowballing searches. Three reviewers (A.L.Y., M.J.S., A.I.) independently extracted data from these nine studies and cross-checked extractions to confirm their reliability. Study design, sample (s) characteristics (both intervention and control) was extracted including the proportion and statistical difference of at-risk relatives who were informed by a proband, contacted the genetics clinic, and had subsequent genetic testing. For the articles with multiple conditions, authors were contacted for additional data and analysis for families with BRCA or Lynch syndrome risk only. Study intervention characteristics were tabulated, and data was compared according to the three outcome categories in the review aim.
The Downs and Black  checklist for randomised and non-randomised healthcare intervention studies was used independently by two reviewers (A.L.Y., M.J.S.) to assess the quality of methodological reporting by studies. Discrepancies were resolved through discussion (Cohen’s Kappa = 0.91). Quality scores of each study are provided in Table 1 and were defined as: limited (<50%), adequate (50–70%), good (71–80%), or strong (score of >80%).
Of the nine studies included in this review (Fig. 1) there were four RCTs and five non-randomised studies. Seven studies exclusively evaluated interventions for probands with BRCA pathogenic variants, and one study evaluated an intervention for those with Lynch syndrome. The remaining two studies included BRCA and Lynch syndrome with additional genetic conditions, which were not included in the final analysis. Study characteristics and outcomes are summarised in Table 1. Results for the three primary outcome measures relevant to the research questions are provided in Tables 2–4 and are described below. The mean quality score  for the nine included papers was 65% (range = 41–89%). The findings and conclusions drawn from studies that had a quality score above 70% were considered to hold greater weight [17,18,19,20].
Most of the interventions described involved either one or two genetic counselling appointments [21, 22] or an appointment with additional telephone genetic counselling sessions [17, 18] or extended sessions post-disclosure . Specific communication techniques included motivational interviewing  and Robert Buckman’s  six-step ‘breaking bad news’ model [19, 20]. Two studies used a multiple-component intervention (face-to-face genetic counselling, written resources, and telephone support) [20, 24]. Two studies were written decision aids, either using Facing Our Risk of Cancer Empowered (FORCE) resources or using the Sharing Risk Information Tool [2, 25]. Two studies compared direct-contact by the genetics clinic with at-risk relatives (DCA) to the family-mediated approach (FMA; proband initiated contact) [21, 22]. For the purposes of this review, the FMA data were the focus of the intervention components and outcomes reported.
Outcome 1: Number of at-risk relatives informed about their risk
Six studies provided a measure of the number of relatives who were informed post-intervention (Table 2). The intervention in four studies included additional/or enhanced genetic counselling [17, 19, 20, 24] and two studies evaluated a written decision aid [2, 25]. Five studies had a standard genetic counselling control [2, 19, 20, 24, 25] and one had no counselling as a control group . Reported percentages of informed relatives in the intervention group ranged from 54.0–95.5%. One study  reported a significant intervention effect. Forrest et al.  found a greater percentage of at-risk relatives were informed when probands were provided with enhanced genetic counselling (specific pedigree discussion, telephone calls to index patient 2–4 weeks post-result disclosure providing guidance about how to approach relatives, and offer to distribute letter to relative directly or via index patient) to encourage family communication about BRCA and/or Lynch syndrome risk, compared to the control group (75% versus 34%, respectively, Pearson χ2(1) = 18.0, p < 0.001).
Outcome 2: Number of at-risk relatives contacting genetics clinics
Three studies reported on the number of at-risk relatives contacting a genetics clinic post-intervention (Table 3). The three interventions varied, including two genetics clinic appointments focused on disclosure , counselling with three additional telephone genetic counselling sessions  or a multiple-component intervention . Reported percentages of relatives in the intervention groups who contacted a genetics clinic ranged from 24.4% to 60.0%. One study had significant results . Forrest et al.  reported a greater proportion of at-risk relatives contacting the clinic for BRCA or Lynch syndrome risk in the intervention group compared to the control group at 24-months post-intervention (60.0% versus 29.8%, respectively; Pearson χ2(1) = 9.7, p = 0.002).
Outcome 3: Number of at-risk relatives having genetic testing after genetic counselling
Six studies provided a measure of genetic testing uptake post-intervention (Table 4).
Interventions included one or two genetic counselling appointments [21, 22], with additional telephone genetic counselling sessions , two written decision aids [2, 25], or a multi-component intervention . The reported percentage of at-risk relatives who were counselled at a genetics clinic and had subsequent predictive genetic testing was between 22.8% and 76.2% (excluding outliers). Two studies were outliers. Sermijn et al.  had 53% (47/89) of relatives come forward for predictive genetic counselling when the process was proband-mediated, with 98% (46/47) of patients have predictive genetic testing. counselling. Garcia et al.  recruited patients at oncology outreach visits, provided written materials about family communication and although all 22 patients communicated with their relatives, only one relative had subsequent testing after 6-months (1/22; 4.5%). Forrest et al.  reported a greater testing rate for relatives in the intervention group compared to the control group, after excluding relatives who were referred interstate (53.3% versus 25.5%, Pearson χ2(1) = 18.0, p < 0.001).
The aim of this review was to examine the efficacy of proband-mediated interventions to improve disclosure of genetic risk to at-risk relatives. Three main outcomes of intervention efficacy were considered: the number of at-risk relatives informed, contacting genetics clinics, and having genetic testing after they were counselled at a genetics clinic. Of the nine studies that met the inclusion criteria, only four studies were of good quality [17,18,19,20] and only one study  reported a significant difference on all three outcome variables, with one additional study  reporting significant findings for attendance at genetics clinics. These findings highlight the need for more better-quality research measuring the outcomes of healthcare interventions to support proband communication to improve the awareness, communication, and uptake of genetic testing by at-risk relatives.
Four identified studies were RCTs that employed interventions delivering family communication focused genetic counselling by a healthcare professional (i.e., genetic counsellor, specialist nurse, or trained psychosocial workers). Two studies used the ‘breaking bad news’  model [19, 20], either as a stand-alone intervention provided in the initial genetic counselling session  or at an additional visit with a nurse, supplemented by a suite of other resources (e.g., pamphlet, videotape, copy of medical records and pedigree) . The other two studies provided telephone counselling, either as an adjunct to standard counselling study at three time-points (increased dosage) , or over two time-points to firstly explore what had been shared based on the patient’s summary letter, and secondly, to brainstorm solutions if barriers existed .
None of the RCTs reported a significant increase in disclosure and uptake of testing by at-risk relatives for BRCA and Lynch syndrome . Baseline disclosure rates [2, 17] and motivation to disclose [19, 20, 24] was high in some studies, potentially influencing ability of interventions used in the included studies to add value. Another possibility is that intervention components were not sufficiently different to standard care, especially if the intervention involved an increased dosage of counselling , making it difficult to demonstrate differences.
The one retrospective cohort study by Forrest et al. , with significant results for all three outcomes, evaluated an intervention that was distinctly different to the counselling received by the control group. The intervention involved detailed, intentional genetic counselling involving pedigree review, documentation, and discussion of relatives not yet informed and discussion of communication barriers and potential solutions, as well as telephone follow-up at two time-points. Depending on the extent to which the proband had contacted at-risk relatives, a letter to relatives was optionally provided to the proband or directly to the relative at the final follow-up time-point. Although the participation rates were low, study results suggested that intentional counselling to improve the proportion of relatives informed and tested can be effective. However, given the small sample size of the study , further research is required to replicate findings.
Skills in conducting pedigree review and addressing family communication barriers are part of the repertoire of genetic counsellors and are easily applicable in a standard genetic counselling appointment . Further research is needed to explore the feasibility of interventions with healthcare professionals other than genetic counsellors. Psychologists, nurses, social workers could also provide additional support to genetics clinics in equipping probands with the skills to communicate with their relatives, particularly as mainstreaming becomes more prevalent .
Forrest et al.  study also suggested that letters summarising important genetic results may be helpful, particularly if the proband lacks confidence in their ability to communicate these clearly and accurately. Importantly, a distinction needs to be made with regards to the studies that involved direct-contact via letter by the genetics clinic (DCA) in comparison to the family-mediated approach (FMA)as used in Forrest et al.. Studies comparing these two approaches  found no difference in psychological distress between DCA and FMA practices and greater uptake of genetic testing using a DCA protocol . However, the DCA protocols used in these studies initially relied on the proband to contact relatives before sending a letter from the genetics clinic [21, 22], a process that mimics the protocol followed by FMA protocols . Indeed, genetics clinics are required to follow the respective legislation and guidelines as to whether a purely DCA protocol is used [13, 14].
There are several limitations in identified studies that need to be addressed in future studies. First, more rigorous studies with adequate power to test hypotheses are required to determine best practice for improving disclosure rates, given that only four studies were RCTs. Second, consideration of a preferred primary outcome is required. The primary outcomes of some of the current studies included genetic risk knowledge, self-efficacy, risk perception and motivation. Although these are important process variables, it is important to measure objective outcomes such as the three outcome variables assessed in this review, using audit and survey data . Third, control conditions (particularly those involving standard genetic counselling) need to be well described, to allow identification of key differences between the intervention and control group [2, 17, 24]. Fourth, given that some of the included studies reported high baseline disclosure rates, targeting recruitment to families facing difficulties with communication may increase the likelihood of detecting intervention effects. This gap in our understanding could uncover the areas where interventions are lacking, including but not limited to, consideration of the relative’s perceptions, assumptions, and experiences. From the family communication literature, it is known that a proband’s emotional reaction towards finding out their test results and their subsequent preventative decisions can sometimes cast a bleak picture of the future, one which their children do not wish to follow . Sharing of testimonials and family group sessions can allow relatives to consider the experiences of others. Moreover, interventions could target certain at-risk groups of relatives known to have lower uptakes of testing, e.g., those in the parental lineage and male relatives. Knowledge of their risk could be increased through awareness groups like the The Movember Foundation (https://movember.com) and engagement with visual and social media platforms.
Limitations of the current review also need to be considered. Variability in the content delivered, specifically standard care procedures, the control/comparison group, frequency of follow-up, outcomes, and definitions of at-risk relatives in identified studies disallowed a quantitative synthesis of trial findings. The percentage of informed at-risk relatives is based on self-reports made by probands, which provides a proxy for the true amount informed, given that it is unethical to approach relatives directly. Moreover, the percentage of relatives informed is dependent on the percentage of probands informed. Studies not conducted in English were excluded, thus some relevant papers may have been omitted.
In summary, a limited number of interventions have measured the efficacy of interventions to improve disclosure of genetic risk to family members. Intentional genetic counselling practices, including pedigree review and strategies to improve communication, with additional follow-up, could improve disclosure rates for families with BRCA and Lynch syndrome. Yet the findings for this are minimal and there is no RCT that has shown a significant result. Given that many of the studies reported a high rate of disclosure but a low uptake of testing amongst relatives, future research should focus on examining post-disclosure variables (e.g., relative’s perceptions and understanding of the test result, emotional reactions towards’ their family member’s decisions) to determine whether these pose barriers to uptake of genetic testing at at-risk family members. The use of a process model, such as the one developed by Lafrenière et al.  provides a framework for understanding the process of communicating genetic test results to family members. Targeted interventions would benefit from drawing from qualitative research and using the model in the pre-intervention development stage, focusing not only on the content of the proband’s disclosure, but also the emotions or sentiments they convey, the decision-making process and reactions of the relatives. With the increase in genetic testing and the demand on genetics clinics to address family communication, this remains a critical area for further research.
Data sharing is not applicable to this article as no new data were created or analysed in this study.
The data generated or analysed during this study can be found within the published article and its supplementary files, along with requests from the authors.
Mucci LA, Hjelmborg JB, Harris JR, Czene K, Havelick DJ, Scheike T, et al. Familial risk and heritability of cancer among twins in Nordic countries. JAMA. 2016;315:68–76. https://doi.org/10.1001/jama.2015.17703
Garcia C, Sullivan MW, Lothamer H, Harrison KM, Chatfield L, Thomas MH, et al. Mechanisms to increase cascade testing in hereditary breast and ovarian cancer: Impact of introducing standardized communication aids into genetic counseling. J Obstet Gynaecol Res. 2020;46:1835–41.
Young AL, Butow PN, Rhodes P, Tucker KM, Williams R, Healey E, et al. Talking across generations: family communication about BRCA1 and BRCA2 genetic cancer risk. J Genet Couns. 2019;28:516–32. https://doi.org/10.1002/jgc4.1055
McGarragle KM, Hare C, Holter S, Facey DA, McShane K, Gallinger S, et al. Examining intrafamilial communication of colorectal cancer risk status to family members and kin responses to colonoscopy: a qualitative study. Hered Cancer Clin Pract. 2019;17:16 https://doi.org/10.1186/s13053-019-0114-8
Healey E, Taylor N, Greening S, Wakefield CE, Warwick L, Williams R, et al. Quantifying family dissemination and identifying barriers to communication of risk information in Australian BRCA families. Genet Med. 2017;19:1323–31. https://doi.org/10.1038/gim.2017.52
Cheung EL, Olson AD, Yu TM, Han PZ, Beattie MS. Communication of BRCA results and family testing in 1103 high-risk women. Cancer Epidemiol Biomark Prev. 2010;19:2211–9. https://doi.org/10.1158/1055-9965.EPI-10-0325
Aktan-Collan KI, Kääriäinen HA, Kolttola EM, Pylvänäinen K, Järvinen HJ, Haukkala AH, et al. Sharing genetic risk with next generation: mutation-positive parents’ communication with their offspring in Lynch Syndrome. Fam Cancer. 2011;10:43–50. https://doi.org/10.1007/s10689-010-9386-x
Pentz RD, Peterson SK, Watts B, Vernon SW, Lynch PM, Koehly LM, et al. Hereditary nonpolyposis colorectal cancer family members’ perceptions about the duty to inform and health professionals’ role in disseminating genetic information. Gen Test. 2005;9:261–8.
Ishii N, Arai M, Koyama Y, Ueno M, Yamaguchi T, Kazuma K, et al. Factors affecting encouragement of relatives among families with Lynch syndrome to seek medical assessment. Fam Cancer. 2011;10:649–54.
Ricker CN, Koff RB, Qu C, Culver J, Sturgeon D, Kingham KE, et al. Patient communication of cancer genetic test results in a diverse population. Transl Behav Med. 2018;8:85–94. https://doi.org/10.1093/tbm/ibx010
Finlay E, Stopfer JE, Burlingame E, Evans KG, Nathanson KL, Weber BL, et al. Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutations. Gen Test. 2008;12:81–91. https://doi.org/10.1089/gte.2007.0037
Menko FH, ter Stege JA, van der Kolk LE, Jeanson KN, Schats W, Moha DA, et al. The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: A systematic review of the literature and implications for clinical practice. Fam Cancer. 2018;18:127–35. https://doi.org/10.1007/s10689-018-0089-z
Young AL, Butow PN, Tucker KM, Wakefield CE, Healey E, Williams R. When to break the news and whose responsibility is it? A cross-sectional qualitative study of health professionals’ views regarding disclosure of BRCA genetic cancer risk. BMJ Open. 2020;10:e033127 https://doi.org/10.1136/bmjopen-2019-033127
Dheensa S, Fenwick A, Shkedi-Rafid S, Crawford G, Lucassen A. Health-care professionals’ responsibility to patients’ relatives in genetic medicine: a systematic review and synthesis of empirical research. Genet Med. 2016;18:290–301.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52:377–84. https://doi.org/10.1136/jech.52.6.377
Eijzenga W, de Geus E, Aalfs CM, Menko FH, Sijmons RH, de Haes HCJM, et al. How to support cancer genetics counselees in informing at-risk relatives? Lessons from a randomized controlled trial. Patient Educ Couns. 2018;101:1611–9. https://doi.org/10.1016/j.pec.2018.05.009
Hodgson J, Metcalfe S, Gaff C, Donath S, Delatycki MB, Winship I, et al. Outcomes of a randomised controlled trial of a complex genetic counselling intervention to improve family communication. Eur J Hum Genet. 2016;24:356–60. https://doi.org/10.1038/ejhg.2015.122
Montgomery SV, Barsevick AM, Egleston BL, Bingler R, Ruth K, Miller SM, et al. Preparing individuals to communicate genetic test results to their relatives: report of a randomized control trial. Fam Cancer. 2013;12:537–46. https://doi.org/10.1007/s10689-013-9609-z
Roshanai AH, Rosenquist R, Lampic C, Nordin K. Does enhanced information at cancer genetic counseling improve counselees’ knowledge, risk perception, satisfaction and negotiation of information to at-risk relatives? A randomized study. Acta Oncol. 2009;48:999–1009. https://doi.org/10.1080/02841860903104137
Aktan-Collan K, Haukkala A, Pylvänäinen K, Järvinen HJ, Aaltonen LA, Peltomäki P, et al. Direct contact in inviting high-risk members of hereditary colon cancer families to genetic counselling and DNA testing. J Med Genet. 2007;44:732–8. https://doi.org/10.1136/jmg.2007.051581
Sermijn E, Delesie L, Deschepper E, Pauwels I, Bonduelle M, Teugels E, et al. The impact of an interventional counselling procedure in families with a BRCA1/2 gene mutation: efficacy and safety. Fam Cancer. 2016;15:155–62. https://doi.org/10.1007/s10689-015-9854-4
Buckman R. How to break bad news. Toronto: University of Toronto Press; 2017.
Forrest LE, Burke J, Bacic S, Amor DJ. Increased genetic counseling support improves communication of genetic information in families. Genet Med. 2008;10:167–72. https://doi.org/10.1097/GIM.0b013e318164540b
Kardashian A, Fehniger J, Creasman J, Cheung E, Beattie MS. A pilot study of the sharing risk information tool (ShaRIT) for families with hereditary breast and ovarian cancer syndrome. Hered Cancer Clin Pract. 2012;10:4 https://doi.org/10.1186/1897-4287-10-4
Patch C, Middleton A. Point of view: an evolution from genetic counselling to genomic counselling. Eur J Med Genet. 2019;62:288–9. https://doi.org/10.1016/j.ejmg.2019.04.010
Lafrenière D, Bouchard K, Godard B, Simard J, Dorval M. Family communication following BRCA1/2 genetic testing: a close look at the process. J Genet Couns. 2013;22:323–35. https://doi.org/10.1007/s10897-012-9559-x
Thank you to the authors who provided a re-analysis of their data: Jan Hodgson, Jo Burke, and David Amor.
No financial assistance was received in support of the study. Open Access funding enabled and organized by CAUL and its Member Institutions.
The authors declare no competing financial interests in relation to the work described. Only one author has a conflict of interest to disclosure, Rachel Williams has presented to Patient Advocacy groups for AstraZeneca, with no promotion of their products.
Ethical approval was not required for conducting the systematic review.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Young, A.L., Imran, A., Spoelma, M.J. et al. Proband-mediated interventions to increase disclosure of genetic risk in families with a BRCA or Lynch syndrome condition: a systematic review. Eur J Hum Genet 31, 18–34 (2023). https://doi.org/10.1038/s41431-022-01200-z
This article is cited by
European Journal of Human Genetics (2023)